In order to restore investor confidence and hedge legacy market downturns, Gilead needs to diversify into other channels of sustainable revenue generation to minimize volatility
Pharmaceutical companies face huge revenue uncertainties after the loss of patent exclusivity; but not all is lost.
How the newest player in Canada’s medical marijuana industry can smoke out the competition
The search for ubiquity in a broken system.
Could drug incubation allow Canada to better compete in the global pharmaceutical industry?
Can medical tourism improve healthcare for Canadians?
The collapse of Western pharmaceutical companies is inevitable